IMGN151

DRUG3 trials

Sponsors

AbbVie Deutschland GmbH & Co. KG, AbbVie

Conditions

Cervical CancerEndometrial CancerFallopian Tube CancerGynecologic CancersHigh Grade Serous Adenocarcinoma of OvaryPlatinum-Sensitive Ovarian CancerPrimary Peritoneal Cancer (PSOC)Primary Peritoneal Carcinoma

Phase 1

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Active, not recruitingNCT05527184

AbbVieCervical Cancer, Endometrial Cancer, Fallopian Tube Cancer +2

Start: 2023-01-11End: 2027-02-01Updated: 2026-02-20

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers

Active, not recruitingCTIS2023-506842-22-00

AbbVie Deutschland GmbH & Co. KGand primary peritoneal cancer (EOC), fallopian tube, recurrent cervical cancer +2

Start: 2025-05-19Target: 169Updated: 2025-12-22

Phase 2

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

RecruitingNCT07024784

AbbVieFallopian Tube Cancer, Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer +1

Start: 2025-07-30End: 2028-02-01Target: 377Updated: 2026-04-03